newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - BIOAGE LABS INC

London. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. I should introduce BioAge Labs. We have with us BJ Sullivan, Chief Strategy Officer. BJ, thank you so much for joining us. Maybe to start with, for those who are less familiar with this story, would you like to give sort of a brief overview of BioAGE and where you're at right now? Happily, and thank you for having us here. Quite a way to kick off London Biotech Week. Thank you to all of you who are attending in person. I recognize we're probably the one thing standing between you and cocktails, so appreciate it. BioAge is a platform company. We're essentially harnessing the biology of human aging to identify promising targets for cardiometabolic disease. Our lead program is BGE-102. It's an oral potential best-in-class NLRP3 inhibitor. and we released phase one data in April this year showing essentially we're able to achieve up to 98% trough inhibition of IL-1 beta, you know, with placebo-like tolerability and a really exceptional tissue distribution profile that enables us to really address inflammation in any compartment of the body. And so, you Know, we are, we have an ongoing phase two trial right now where we're testing three doses of BG-102 and trying to understand the dose-response relationship between, obviously, dose and degree of IL-1 beta suppression and a rich set of inflammatory and metabolic markers. And so we're really trying to tease that apart and understand, you know, the tolerability as well as the impact of these biomarkers over a three-month period. So we think that's going to be a very rich data set. we're targeting data, you know, committed to data at the end of this year. We also have the 12DME proof of concept trial in diabetic macular edema. And so this is really our beachhead into ophthalmology, and it's enabled by, you know, this tissue distribution profile that gives very high free drug in the retina. And so, this trial is looking at BG1 and 2 both as a monotherapy as well as in combination with VEGF in diabetic Macular Edema over three months of treatment, and we're powered for, you know, essentially about a line of improvement in BCDA. And so we're very excited about, you Know, that ongoing trial, and that's reading out at the end of next year. So that is our lead program. We're also developing two APJ agonists. So we're developing both an oral and a parenteral version. This is a target that in our cohort is among the most highly associated with both longevity as well as preservation of physical function. So We're very excited to be back in the clinic with this target. We're, you know, guiding to filing our IND for the first APGA Agonist Program by the end of this year. And we're very exciting at that time to really debut the program and talk in more detail about our clinical development strategy. But this is something that, you Know, has the potential, at least in preclinical models, to double weight loss and completely restore body composition in obesity. So I'm happy to talk further about that later. Thank you so much. Maybe we can start with BG102 in ASCVD. It's an NLRP3 inhibitor. Obviously, there's some other NLLP3 inhibitors in development, and there's an X7. Can you talk a little bit about your differentiation? I think you have a novel binding site. Right. And what advantages do you think this may confer in the clinic? So NLRP3 is a target that has been prosecuted now for decades. And a lot of it is, you know, Pfizer brought the first one into the clinic two decades ago, and a lot of other approaches to targeting NLLP3 are essentially derivatives of that chemotype or novel chemotypes targeting the same binding site, which is the ATPase pocket. We decided to take a totally de novo approach. We did a Dell screen. We blocked that binding site. We were intentionally looking for, you know, novel binding and optimizing the profile really for brain penetration and tissue sort of distribution that was, you know, suboptimal in sort of historical programs. And so we've done very detailed characterization of this binding site with Matthias Gungor at the University of Bonn, who's really an expert in, you know, crystallizing the NLRP3 protein. and, you know, what we, part of this characterization is really what we've shown is that we're able to both inhibit assembly of the inflammasome as well as trigger the disassembly of the inflammasome. So as it goes from a monomer to a decameron, these different states of activation, you Know, we're to inhibit it. And that may explain, you know, why we're Able to achieve such profound reduction, you Know, in IL-1 beta. So in our, in our phase one trial, you know, at the 120 milligram dose, what we saw was essentially 98% trough suppression. So at the end of the 24-hour period, meaning you get almost, like, pretty much complete target inhibition for that full 24 hours. You know, and so that, we think we're really differentiated in the depth of that target inhibiton, which may be explained by that binding type. Great. There are a lot of indications that could potentially be addressed by NLRP3. what indications do you think your asset is most suited to i guess for the cns penetration right going off to dme but right so the um so you know i think to just give everyone a little bit of context nlrp3 is really um a mediator of sterile inflammation in the body and so um as opposed to an innate immune response to a pathogen um nlr p3 is activated um in response to a lot of sterile stress signals. So that can be metabolic stress. It can be hyperglycemia, oxidized LDL, cholesterol, crystals. That's why you see it very highly associated with cardiometabolic disease. And so there are a broad range of indications that we feel like we can address with this target. DME is one where we really feel we're able to take advantage of this tissue distribution profile. Again, we get very high free levels in the retina. And So we can address a disease that's known to be driven, at least in part, by inflammation, you know, in a very convenient dosing format. But we're also able to address, we think, the sort of systemic disease phenotype, right? So hyperglycemia and diabetes causes metabolic stress throughout the body, causes systemic inflammation. And so when we're treating DME, you Know, we're able to adjust, you think, to the systemic disease as well, right, So that there are benefits for, you know, broad metabolic benefits in addition to directly targeting the DME pathology specifically. We recently saw the full Zeus data at AHA, which is NOVA, IL-6, ZILTI. Can you walk us through your thoughts on that and what data points helped clarify kind of the reason for this trial failing and the key implications for BGE10 is two. Right. So maybe to set some context, we know that intervening and targeting inflammation can result in MACE benefit in cardiovascular disease. So colchicine, which is an indirect NLRP3 inhibitor, has quite meaningful MACE benefits in certain patient populations. We saw in the CANTOS trial with canakinumab that targeting IL-1 beta can result and very meaningful, you know, MACE benefits. So we were surprised, certainly, when Zeus spread out with a hazard ratio of about one, right? So this is targeting IL-6, which is a downstream cytokine. So going into the AHA presentation, I think there were basically two hypotheses. One is that the population enrolled here, which was, you knows, ASCVD and comorbid CKD was too far gone, the disease was too severe, and the risk wasn't modifiable at that stage. The other hypothesis was that IL-6 is too far downstream. So you have inflammation, like NLRP3 is activated at the plaque. You know, it, you know, is this sort of this cytokine processing of IL-1 beta, IL-18, and triggers pyreptosis, this inflammatory cell death that happens at the level of the plaque, right, and secretes IL-2 beta, which is sort of a short-lived cytokine that operates at the plaque level, you know, and then that downstream turns into an IL-6 signal, which then becomes more of a systemic alarm signal, right? And so maybe IL-16 is too far downstream, and that's actually really a biomarker and not really the right causal target. And so, you Know, when we, you Now, in looking at the full Zeus data set, you now, what you saw is that there was really no subgroup signal. And so you saw patients with, you Know, very, very poor GFR status in the trial, you know, their outcomes weren't any different from patients who had less severe CKD and certain kidney function. So in my view, at least, it sort of seems to strongly support the idea that it was the wrong target and it's too far downstream. Now, we'll see with Artemis, this is an acute MI population. In the first half of next year, it's a very different population. If there's a signal there, you're ready to jump right back into it. This was sort of our lead indication. We've done a lot of the preparatory work, especially related to CMC preparedness. So a lot long lead time items to essentially enable, you know, the initiation of a trial at the scale of an outcomes trial. So that's not a priority for us right now, you know, given the Zeus trial. Not that we think the biology is less meaningful. In fact, I think that the Zeus results support the upstream biology as being sort of unequivocally, maybe more like causal. You know, but certainly the investor appetite to, you know, run a five-year, half-a-billion-dollar outcomes trial where you're translating, you now, a biomarker into a hard outcome, that's changed a lot, you Now, since the Zeus trial. So, we're, you know, we've doubled down on 12-DME, and we really think of this as a beachhead into a broader ophthalmology strategy. I think that there are a lot of indications, like uveitic macular edema, geographic atrophy, where NLRP3, we think, plays a very important role in the disease pathology. And we've also signaled that, you know, we'll add an additional indication for the NLLP3 program and really looking at, you know, where has the IL-1 and IL-6 experience showed efficacy in terms of actually moving an approvable endpoint, right, and sort of following that signal minimally as sort of an oral equivalent targeting, you know, upstream biology, but ideally capturing incremental efficacy, you know, because you're going upstream, you're capturing IL-1 beta and IL-18 as well. You're also capturing, you know, pyroptotic cell death. And we think that that's an important feature of a lot of diseases. And so, you Know, that's sort of the way we're thinking about evolving the BG-102 strategy in the post-use world. So your sort of move away from cardiovascular disease isn't necessarily move away. It's just not not yet yeah i mean all of that all of that preparation remains intact you know but we're we're focusing elsewhere and again if they um you know artemis has a um you know surprisingly surprisingly definitive signal we'd be you know fast to follow there um and if you know for example lily has their ventix um nlmp3 program and if they decide you know to take that into an outcomes trial and that really catalyzes interest in this approach you know we would be fast to following there as well. So we're certainly watching the landscape very carefully, but right now, you know, we're focusing on ophthalmology and then, you know an additional indication yet to be announced and focusing there on, you now, where has the biology been de-risked by this sort of cytokine neutralization experience and also indications where, you, know, it's practical for a smaller biotech to advance it through, you kno, POC if not, you kow, sort of a pivotal trial. like. Are there any other developments in the field that would cause you to take another look at cardiovascular disease earlier? Because I know some other companies are doing trials in CAD and CAD. You know, anything definitive that comes out of those trials, there are arterial imaging trials that are going on. There are a lot of different, you know, this work continues, Right. I think, you know, from our standpoint, we're watching carefully and we're ready. But but but for the near term, it's focusing elsewhere. And what would that look like for you in terms of the next steps? If you said, OK, let's let's do this after Artemis or something. What what type of study would you would you like to do? You know, it'S impossible to say a priori what that what that would look like. But I think we're certainly prepared to move quickly from that standpoint, you know, if there is a, you know, a bullish or a de-risking signal from, you know, from, competitor or sort of orthogonal programs. And looking at your phase one data, can you go into a bit more detail about the biomarker data? you did touch on it in your intro. And why is this exciting? Is it better than other approaches in terms of the level of CRP reduction and other things? How should we compare that to the other data sets? So in our phase one, we did a standard sort of healthy volunteer SADMAP. And we also were inspired by the Ventix data, their trial results, where they showed essentially they had run a three-month trial that's not dissimilar from our quality B trial. And as part of that, they showed that they achieved their maximum biomarker reductions within the first couple of weeks, and those were essentially sustained through the dosing period. And so we added two cohorts of obese and inflamed individuals to the phase one study where we looked at 120 milligrams QD for two weeks and 60 milligrams QD for three weeks. And, you know, we were, you know, in the 120 milligram group, we essentially saw 98%, again, IL-1 beta suppression, you know, at trough. So, essentially, again, 24 hours of complete pathway inhibition, you know with placebo-like tolerability. And so, we were incredibly pleased with those results. And you know in both of the dose groups, we saw essentially an 86% reduction in CLP and sort of concordant reductions in IL-6 and fibrinogen in the downstream markers. And so that's a lot of the genesis of the QUAL-CV trial now is understanding the dose response, what level of IL-1 beta suppression translates into what magnitudes of inflammatory and metabolic markers and assessments that we'll be measuring. So we thought we're, you know, the phase one results were essentially as good as we could have hoped for, if not better. And we also did lumbar punctures, right, in those, you know, in several cohorts of patients and saw essentially that, you know, recapitulation of our non-clinical data was showing very nice exposure in the CSF and, you know, certainly related to, you know, our ability to penetrate the blood retinal barrier, you know we haven't done the peak the aqueous sort of ocular peak in humans yet but certainly we see across the clinical species you know including NHPs very nice free levels in the retina so it all of that data lines up very nicely. You have a phase two readout coming up I believe by the end of this year. That's right. With this asset in obesity and inflammation so how should we be thinking about this? How important is it now that you're kind of not necessarily going into ASCBD? And what do you need to show with this readout? Yeah, so we think it's a very important readout for us. And it's very important data set. And I think it is really agnostic to ASCVD or other indication opportunities for BG102. These individuals are similar to the patients we had in our phase ones that are obese. They have elevated CRP at baseline. They also have an additional cardiovascular risk factor. And we'll be measuring, you know, a very rich set of inflammatory and metabolic biomarkers over a three-month treatment period, as well as MRI imaging of the liver, for example, looking at liver fat, liver inflammation. And so we're going to get a very good sense of, you knows, dose response, you now, there, and helping us, you know, with go-forward dose selection, as Well as understanding the potential benefits of NLRP3 you know, in the broader suite of cardiometabolic diseases. I mean, it's been implicated in, you know glucose control and, you, know, kidney function in addition to sort of, you know, more cardiovascular disease like, like atherosclerosis. So we're, we're hoping to find a lot of sort of motivating signals in that, in that data set. And importantly too, you know, we, the BG one or two is very well tolerated. It was sort of placebo-like tolerability in the phase one. And we, we hope to extend that over just a longer treatment period. And with the DME program, you have Quell DME, can you just walk us through that program maybe? Yes, so this is, Quell DME is our beachhead endophthalmology, it's looking at BG102 as a monotherapy, so comparing patients to their own baseline. It's also comparing VEGF to VEGEF plus BG-102, and this is basically the treatment, the two two paradigms where IL-6 has shown benefits. So, you know, if you look at Roche's, the Mickey Bar program, you knew they showed about a line of improvement in BCDA in both of those different settings. And we're really trying to recapitulate that exact design. They showed maximum separation by about two months. So we feel like three months is a good dosing window to sort of capture that maximum benefit and um you know we'll you know the trial is is powered for for bcba for four letters of improvement um but of course we're going to be looking at a variety of retinal parameters as well as systemic markers right because i you know i want to emphasize that um you no it's a it is a very convenient way to to treat dme specifically and inflammation of retina and these are patients where who there's a lot of resistance understandably to intravitreal therapy in terms of very large segment of patients who are in the sort of watch your weight category who may have you know they've got um a swollen macula they made up some compromise in vision but they don't want to get an intramural therapy incumbent every month or every quarter and so we think that's highly addressable you know and then on the other end of the spectrum there are patients who are a veg peps you know but they have incomplete disease you know control um and and sort of continue to compromise vision and there this is an additional modality to improve disease control. And so I would say, too, that, like, you know, we're motivated by the IL-6 experience. So if we can deliver IL-16-like efficacy with an oral that's well-tolerated, we think that that's an enormous win for patients. You know, but the biology is distinct, and so we are looking at, you know what additional benefit there may be by going upstream and capturing IL-1 beta, which directly induces VEGF by capturing IL-18 and then this pyroptotic aspect of NLRP3 which contributes to essentially deterioration in the integrity of the microvasculature in the retina, right? And so there's both like, you know, NLLP3 has both the sort of standard or canonical cytokine inflammatory downstream biology, but also this sort of cell-intrinsic pyroprototic biology that we think is relevant in DNA. Okay. You mentioned that it could be even more effective than IL-6 because it's upstream. Could you go into a little bit more detail on that? Yeah. So the, you know, again, I think, you Know, our sort of minimum profile here is if we can recapitulate IL-16, that's a huge win for us. But it does, but it does capture this upstream biology, right? And I think, you know, one of the key features is of diabetic macular edema is that you get compromised microvasculature, right? And a lot of that is driven by this inflammatory cell death that compromises barrier function and contributes to edema. And so, you Know, for example, when we run our very straightforward preclinical model where you create profound hyperglycemia in a mouse, you get a very profound diabetic retinopathy phenotensin road instead of immaculate so it's not exact but um you get a lot of um leakage into the into the eye and you can you can very easily visualize that and quantify that that's completely corrected by nlp3 division um and additionally when you sort of the macro view of it then zoom in and you look at um ihg sections and you looks for the integrity of the microvasculature, you know, hyperglycemia alone causes, you know, impairments in that integrity, which, again, are really fully rescued by BG102, you know, delivered orally. And so we think that there's a lot of biology here that may be distinct by going upstream. And obviously the anti-VEGF are quite well entrenched in the standard of care. How do you envision kind of an oral being um sort of integrated into this market yeah so so again the 40 percent of patients are in this watch and wait category where they're like in earlier stages of disease and you know you talk to you know our investigators and all of our sites about this like you know there's a lot of resistance to intravitreal therapy and it's understandable right no one wants to go in and come and get injected it's a burden um and it sort of inherently unpleasant um and so we think that there's a huge value proposition there. You can help manage the disease and delay initiation of therapy. This is something that I think patients would be very receptive to. I mean, you see even in trials of VEGF, you know, the amount of disease control you get there versus the real world scenario where patients have to, you Know, on their own volition come in therapy, they're quite different. You know, and then again, on the other end of the spectrum, you have patients who are compliant with VEGF, but remain, you know, especially partially refractive, right? And they're adding additional mechanism to get better disease control is sort of the primary value proposition, you knows, saving an injection, you mean, you don't have a secondary value proposition in that case. And I would say, too, with sort of quality, I mean, we think this is sort of our beachhead into ophthalmology, and there are several other indications that can be de-risked by this and even just establishing you know a clear pkpd relationship in the eye you know which will motivate motivate further work here remind us when we should expect the quality me readout so we're guiding to data and at the uh in the second half of next year okay great and at that point you could move into ga or other geographic atrophy is an indication of very high interest to us yes it's eviatic macular edema to um two indications where you you know, we think NLRP3 really plays a central role. Great. Should we talk about your APJ agonist? Yes. No, very happily. So we are, you know – this is an exciting milestone for us. We're going to be back in the clinic very shortly with, you know, an APJ Agonist. So this is a target that in our cohorts is one of the most highly associated with both longevity as well as preservation of physical function. And we've shown that when you combine APJ agonism with a GLIP or actually any mechanism that causes appetite depression, you can double weight loss and fully restore body composition of the mice back to lean controls. And so we think that there are a number of whites-based opportunities here in obesity, both on the oral and parenteral side. So we're advancing two APJ Agonists in parallel, both routes of administration. We haven't disclosed which one we're going to file an ID for by the end of the year, but there are a number of white space opportunities on both of those fronts. And we have experience with APJ. We licensed an APJ agonist from Amgen, who was ultimately discontinued due to compound-related issues. But what we demonstrated there as proof of concept was when you put older patients on bed rest for 10 days, they undergo very profound muscle atrophy and so you can see that the gross level just muscle size muscle quality so fatty infiltration of the muscle as well as doing molecular measurements of muscle protein synthesis and other um sort of molecular assessment you know very a very profound muscle signal and preservation of muscle and so um you know we are very excited to take you um you know this next gen program when we file an ind at the end of this year you know and speak in detail about our clinical development there. But, you know, we're excited to be back in the clinic with ABJ. You mentioned your past ABJ program had a liver safety signal. Can you talk about how this asset is different from that one? Yes. Right. So that one had a what was sort of all experts agree is sort of the classical idiosyncratic liver injury, which is really an immunological response to a specific compound and chemotype and so our goal for the oral small molecule is one it's a totally distinct chemistry it has nothing to do with um you know the prior compound and you know we were we're optimizing for dose and so you know the target profile here is really under 100 milligrams you know a day and so that that meaningfully lowers your risk i mean that that program we were dosing at 300 milligrams qd and BID, and just having a higher dose increases your risk. So, you know, one is a totally novel chemotype in cancer chemistry, and then two is really optimizing for a low QD dose. Okay. And then beyond these two assets, I think you have a couple of partnerships, one with Lilly, one with Novartis, and you obviously have a broader platform. So can you talk about to what extent you can kind of those discovery partnerships and what else we could potentially look forward to in the future from bio age yep so the um so again we have a we have a sort of human aging platform where we've partnered with the leading biobanks around the world that have been phenotyping and biosampling participants for up to 50 years so we we track them from healthy middle age to death and we understand not only you know macro health outcomes or longevity but also detailed phenotypic physical function cognitive function um you know specific disease incidents. And so we can ask the question, like, what is the biology in middle age that is predictive of all of these different outcomes, you know, with age? And so Lilly and Novartis are two pharmas that are very public in their investment and interest in aging biology as sort of a lens for target discovery. With Lilly, we're working on developing therapeutic antibodies for novel targets that we identified in our platform. And with Novartis, it's really around target discovery, so it's a bit earlier stage. And what we're doing is we're looking for, you know, targets that essentially mediate both the benefits of exercise and also predict healthy longevity, essentially. And so we're contributing our aging data sets, and Novartise is contributing interventional exercise data sets. So, you know, that's the ongoing work we have in terms of collaborating with those two companies. Now, these programs are earlier stage, and so we haven't disclosed, you know, what the targets are or more detail beyond that. Okay. And then just finally, on your cash runway, can you remind us what your current cash position is and what the runway is there? Yeah. So, we recently reported we have about a little over $350 million in cash. So that gets us, you know, essentially through 2029 and finances all of the, you know, all the work we've been talking about. So NLRP-free suit through QLCD, QLTME, and proof of concept for an additional vacation. It also funds the APJ programs through proof of concept. And so, you know, we feel like we're able to create a lot of value with the cash balance on hand. Perfect. Well, I think that's all we have time for, but thank you so much, Vijay, for joining us. Thank you very much for having us.

Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC